论文部分内容阅读
[目的]探讨奈达铂化疗同步放疗治疗局部晚期鼻咽癌的疗效和不良反应。[方法]84例局部晚期鼻咽癌患者,随机分为奈达铂组(45例)和顺铂组(39例),两组在根治性放疗的同时给予奈达铂(奈达铂100mg/m2静滴d1、22、43)或顺铂(顺铂100mg/m2,静滴d1、22、43)化疗。[结果]奈达铂组CR42例(93.3%),PR3例(6.7%),顺铂组CR35例(89.7%),PR4例(10.3%),两组疗效差异无显著性(P>0.05)。奈达铂组和顺铂组胃肠道反应发生率分别为22.2%和46.2%,差异有显著性(P<0.05),两组骨髓抑制、肝、肾功能损害、皮肤黏膜反应发生率差异均无统计学意义(P>0.05)。[结论]奈达铂化疗同步放疗治疗局部晚期鼻咽癌疗效确切,不良反应可耐受。
[Objective] To investigate the efficacy and adverse reactions of nedaplatin chemotherapy with concurrent radiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. [Methods] 84 patients with locally advanced nasopharyngeal carcinoma were randomly divided into nedaplatin group (n = 45) and cisplatin group (n = 39). The two groups were treated with nedaplatin (nedaplatin 100 mg / m2 intravenous d1,22,43) or cisplatin (cisplatin 100mg / m2, intravenous d1,22,43) chemotherapy. [Results] There were no significant differences between the two groups (P> 0.05). [Results] There were no significant differences in CR42 (93.3%), PR3 (6.7%), C35 (89.7%) and PR (10.3% . The incidences of gastrointestinal reactions in the nedaplatin group and the cisplatin group were 22.2% and 46.2%, respectively (P <0.05). The differences in the incidence of bone marrow suppression, hepatic and renal dysfunction, and mucocutaneous response between the two groups were statistically significant No statistical significance (P> 0.05). [Conclusion] Nedaplatin combined with concurrent radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma has definite curative effect and tolerable adverse reactions.